DE69401658T2 - Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese - Google Patents

Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese

Info

Publication number
DE69401658T2
DE69401658T2 DE69401658T DE69401658T DE69401658T2 DE 69401658 T2 DE69401658 T2 DE 69401658T2 DE 69401658 T DE69401658 T DE 69401658T DE 69401658 T DE69401658 T DE 69401658T DE 69401658 T2 DE69401658 T2 DE 69401658T2
Authority
DE
Germany
Prior art keywords
dgj
glycolipid
dnj
cells
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69401658T
Other languages
German (de)
English (en)
Other versions
DE69401658D1 (de
Inventor
Terry Butters
Raymond Dwek
Gabrielle Neises
Frances Platt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Monsanto Co
Original Assignee
GD Searle LLC
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/061,645 external-priority patent/US5399567A/en
Application filed by GD Searle LLC, Monsanto Co filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69401658D1 publication Critical patent/DE69401658D1/de
Publication of DE69401658T2 publication Critical patent/DE69401658T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE69401658T 1993-05-13 1994-05-11 Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese Expired - Fee Related DE69401658T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/061,645 US5399567A (en) 1993-05-13 1993-05-13 Method of treating cholera
US08/102,654 US6291657B1 (en) 1993-05-13 1993-08-05 Deoxygalactonojirimycin derivatives
PCT/US1994/004974 WO1994026714A1 (en) 1993-05-13 1994-05-11 Novel deoxygalactonojirimycin derivatives

Publications (2)

Publication Number Publication Date
DE69401658D1 DE69401658D1 (de) 1997-03-13
DE69401658T2 true DE69401658T2 (de) 1997-06-12

Family

ID=26741316

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69401658T Expired - Fee Related DE69401658T2 (de) 1993-05-13 1994-05-11 Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese

Country Status (11)

Country Link
US (3) US6291657B1 (OSRAM)
EP (1) EP0698012B1 (OSRAM)
JP (1) JP3636363B2 (OSRAM)
AT (1) ATE148456T1 (OSRAM)
AU (1) AU6783294A (OSRAM)
CA (1) CA2159988C (OSRAM)
DE (1) DE69401658T2 (OSRAM)
DK (1) DK0698012T3 (OSRAM)
ES (1) ES2097653T3 (OSRAM)
GR (1) GR3022554T3 (OSRAM)
WO (1) WO1994026714A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798366A (en) * 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
JP2003506406A (ja) 1999-08-10 2003-02-18 ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード 長鎖ｎ−アルキル化合物およびそのオキサ誘導体
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
US7994198B2 (en) 2002-07-17 2011-08-09 Actelion Pharmaceuticals Ltd. Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase
WO2004007453A1 (en) 2002-07-17 2004-01-22 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
GB0229476D0 (en) * 2002-12-17 2003-01-22 Oxford Glycosciences Uk Ltd Novel process
ES2619353T3 (es) 2003-01-31 2017-06-26 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
GB0313677D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compound
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
CN1906162B (zh) * 2003-11-12 2012-05-23 阿米库斯治疗学公司 用于治疗戈谢病的羟基哌啶衍生物
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US20090111812A1 (en) * 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
CA2719567A1 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
CN102427804A (zh) * 2009-03-27 2012-04-25 牛津大学之校长及学者 降低胆固醇水平的脂质体
WO2010111711A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
CA2822493C (en) 2010-12-23 2018-11-20 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2014032187A1 (en) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
CN104918619B (zh) * 2013-01-09 2019-04-02 阿米库斯治疗学公司 稳定的肠胃外dnj组合物
US11306058B2 (en) 2017-06-01 2022-04-19 Idorsia Pharmaceuticals Ltd Crystalline form of N-butyldeoxygalactonojirimycin
EP4034256B1 (en) 2019-09-25 2025-11-19 Assia Chemical Industries Ltd. Solid state forms of lucerastat salts and process for preparation thereof
WO2022132992A1 (en) 2020-12-16 2022-06-23 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade 1-deoxygalactonojirimycin compounds
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
WO2025017212A1 (en) 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
WO1987003903A1 (en) 1985-12-23 1987-07-02 Fred Hutchinson Cancer Research Center Regulating retroviral replication, infection, and pathogenesis
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5030638A (en) 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
EP0536402A4 (en) 1990-06-29 1993-05-12 Nippon Shinyaku Company, Limited Piperidine derivative
US5128347A (en) * 1990-10-18 1992-07-07 Monsanto Company Glycosidase inhibiting 1,4-dideoxy-4-fluoronojirimycin

Also Published As

Publication number Publication date
ATE148456T1 (de) 1997-02-15
WO1994026714A1 (en) 1994-11-24
US6291657B1 (en) 2001-09-18
DK0698012T3 (OSRAM) 1997-02-17
EP0698012B1 (en) 1997-01-29
GR3022554T3 (en) 1997-05-31
AU6783294A (en) 1994-12-12
US5786368A (en) 1998-07-28
JP3636363B2 (ja) 2005-04-06
CA2159988C (en) 2007-01-09
EP0698012A1 (en) 1996-02-28
JPH08510244A (ja) 1996-10-29
CA2159988A1 (en) 1994-11-24
DE69401658D1 (de) 1997-03-13
ES2097653T3 (es) 1997-04-01
US5580884A (en) 1996-12-03

Similar Documents

Publication Publication Date Title
DE69401658T2 (de) Verwendung von deoxygalactonojirimycin derivaten zu hemmung der glycolipid synthese
DE69735669T2 (de) Deoxynojirimycin derivate und ihre verwendung als glukosesylceramidase-inhibitoren
DE69824421T2 (de) Verfahren zur Behandlung von lysosomalen Speicherkrankheiten mit ZNS-Beteiligung
US5399567A (en) Method of treating cholera
DE60225671T2 (de) Pharmazeutisch wirksame piperidinderivate
DE69821520T2 (de) Verwendung von alkylierten iminozuckern zur behandlung von multipler medikamentenresistenz
DE60003409T2 (de) Kombination von n-butyldeoxynojirimycin (nb-dnj) und glykolipid vermindernden enzymen in therapie
DE69623899T2 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
JPWO1995005177A1 (ja) 神経疾患治療剤
DD283938A5 (de) Verfahren zur herstellung von antineoplastisch wirksamen pharmazeutischen kombinationspraeparaten
Erickson et al. N-Hexyl-0-glucosyl sphingosine, an inhibitor of glucosyl ceramide, β-glucosidase
DE69809944T2 (de) Fettsäuren als eine nährungsergänzung
DE3009071A1 (de) 2-isopropylaminopyrimidinhydroxyderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE2349538C2 (de) Arzneimittel zur Behandlung von Lebererkrankungen
DE69023045T2 (de) Carboxamidderivate.
EP0300960B1 (de) Neue pharmazeutische Präparate sowie neue Lactosylverbindungen und ihre Herstellung
DE19810999A1 (de) Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten
EP1686984B1 (de) Verwendung von c-(2-phenyl-cyclohexyl)-methylaminverbindungen zur therapie von angststörungen
EP0669826B1 (de) (-)-metrifonat enthaltendes arzneimittel
DE2546001A1 (de) Immunostimulierende phospholipide und sie enthaltende arzneimittel
DE69632117T2 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE102005008312A1 (de) Verwendung deuterierter N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]acatamide und deren pharmazeutisch verträglicher Salze sowie diese Verbindungen enthaltende Arzneimittel
Vanni Studying multivalent iminosugar glycomimtics to target enzymes for healthcare applications
EP1521761A2 (de) Cdg-therapie mit mannose
Bassi et al. Cultured cerebellar granule cells, but not astrocytes, produce an ester of ganglioside GD1b, presumably GD1b monolactone, from exogenous GD1b

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee